A detailed history of Stifel Financial Corp transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Stifel Financial Corp holds 1,843,289 shares of BCRX stock, worth $14 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,843,289
Previous 1,843,652 0.02%
Holding current value
$14 Million
Previous $11.4 Million 22.95%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $2,326 - $3,154
-363 Reduced 0.02%
1,843,289 $14 Million
Q2 2024

Aug 13, 2024

SELL
$4.13 - $6.79 $1,172 - $1,928
-284 Reduced 0.02%
1,843,652 $11.4 Million
Q1 2024

May 13, 2024

SELL
$4.89 - $7.65 $581 - $910
-119 Reduced 0.01%
1,843,936 $9.37 Million
Q4 2023

Feb 12, 2024

BUY
$4.98 - $6.77 $179 - $243
36 Added 0.0%
1,844,055 $11 Million
Q3 2023

Nov 13, 2023

SELL
$6.71 - $7.92 $3,589 - $4,237
-535 Reduced 0.03%
1,844,019 $13.1 Million
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $3,340 - $4,228
480 Added 0.03%
1,844,554 $13 Million
Q4 2022

Feb 13, 2023

SELL
$10.5 - $14.2 $22,050 - $29,820
-2,100 Reduced 0.11%
1,844,074 $21.2 Million
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $41,541 - $57,018
-3,850 Reduced 0.21%
1,846,174 $23.3 Million
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $2,509 - $5,685
-318 Reduced 0.02%
1,850,024 $19.6 Million
Q1 2022

May 13, 2022

BUY
$11.56 - $19.76 $9,456 - $16,163
818 Added 0.04%
1,850,342 $30.1 Million
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $9,279 - $12,831
-830 Reduced 0.04%
1,849,524 $25.6 Million
Q1 2021

May 14, 2021

SELL
$7.37 - $13.61 $1.41 Million - $2.61 Million
-191,745 Reduced 9.39%
1,850,354 $18.8 Million
Q2 2020

Aug 14, 2020

SELL
$1.9 - $5.61 $93,423 - $275,843
-49,170 Reduced 2.35%
2,042,099 $9.73 Million
Q1 2020

May 14, 2020

BUY
$1.6 - $4.11 $3.35 Million - $8.6 Million
2,091,269 New
2,091,269 $4.18 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.